Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

This study is currently recruiting participants.
Verified April 2012 by University of Oklahoma
Sponsor:
Collaborator:
Ikaria Holdings Inc.
Information provided by (Responsible Party):
Kris Sekar, University of Oklahoma
ClinicalTrials.gov Identifier:
NCT01220687
First received: October 7, 2010
Last updated: April 11, 2012
Last verified: April 2012

October 7, 2010
April 11, 2012
April 2011
November 2012   (final data collection date for primary outcome measure)
To investigate whether iNO decreases the supplemental oxygen exposure in the preterm infants who require continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) during resuscitation as per NRP protocol. [ Time Frame: 20 minutes ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01220687 on ClinicalTrials.gov Archive Site
To determine HR, RR, O2 saturation, cerebral O2 extraction, need for intubation and PPV in the first 20 min of life; to investigate potential impact of resuscitation with iNO on hemodynamics within the first 72 hours of life. [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation
Administration of Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation Protocol: A Pilot Trial

This study hopes to determine whether nitric oxide along with oxygen during the first 20 minutes of life in infants needing help with breathing will reduce the percentage and total exposure to oxygen during that time frame. Although the use of oxygen in management of breathing is an important part of supporting baby immediately after delivery, there is more evidence that too much exposure to oxygen may lead to potential problems for your baby later. Oxygen exposure can be harmful to premature babies developing lungs.

Current Neonatal Resuscitation Program (NRP) guidelines suggest the use of supplemental oxygen up to FiO2 of 1.0 during neonatal resuscitation for both term and preterm newborns. Exposure to supplemental oxygen in preterm babies has been shown to have significant toxicity. Even minimal exposure in the first hours of life has been shown to be associated with morbidity including later onset of cancer. The transition from fetal circulation to neonatal circulation is a complex process requiring lung inflation and decrease in pulmonary vascular resistance. Endogenous nitric oxide, along with oxygen, plays a major role in facilitating this transition by decreasing pulmonary vascular resistance. It is not known whether exogenous nitric oxide would facilitate this transition. In this study, we propose a novel approach to resuscitation of preterm infants where inhaled nitric oxide (iNO) will be used as an adjunct to oxygen with the primary goal of reducing supplemental oxygen exposure. This study is designed to be a double-blind, randomized, -placebo- controlled pilot trial with strict monitoring of parameters during transition in the delivery room.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Prematurity
  • Low Birth Weight
  • Drug: Inhaled Nitric Oxide
    Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). FiO2 will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
    Other Name: Nitrogen
  • Other: Nitrogen
    Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). FiO2 will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
  • Placebo Comparator: Placebo
    Intervention: Other: Nitrogen
  • Placebo Comparator: iNO
    Intervention: Drug: Inhaled Nitric Oxide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Infants that are 25 0/7 - 31 6/7 weeks gestation
  • Infants who require CPAP or PPV during delivery room resuscitation.

Exclusion Criteria:

  • Refusal of consent
  • Known complex congenital anomalies of the heart or lungs
  • Known major genetic defects
  • Hydrops fetalis
Both
up to 2 Minutes
No
Contact: Kris Sekar, M.D. 405-271-5215 kris-sekar@ouhsc.edu
Contact: Michael McCoy, MS 405-271-5215 michael-mccoy@ouhsc.edu
United States
 
NCT01220687
15503
No
Kris Sekar, University of Oklahoma
Kris Sekar
Ikaria Holdings Inc.
Principal Investigator: Kris Sekar, M.D. University of Oklahoma
University of Oklahoma
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP